SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential, highlighting its speed and efficiency compared to other blockchains like Ethereum. Discussions also involve meme coins built on Solana, with some users anticipating a strong rally. Additionally, the recent Alpenglow upgrade, aimed at boosting transaction speeds, has generated buzz.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

$SNAP is trending as traders discuss potential catalysts including AI integration, a possible buyout, and speculation around increased interest from Reddit's WallStreetBets community. Community members are actively debating price targets, potential acquirers, and the impact of AI on the platform's future, while also noting the stock's high short interest and recent trading volume.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending amid high trading volume and social media buzz, with community members actively discussing potential short squeezes and a climb towards a target price of $10. Speculation around upcoming news, such as a new CEO announcement, and broader market factors, like potential interest rate cuts, appear to be fueling optimism. Despite some bearish sentiment and a recent critical report from Citron Research, many investors express confidence in OPEN's long-term potential.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to recent bullish momentum and community excitement around upcoming airdrops and staking. The community believes $BROKE has strong long-term potential, citing the active developer, engaged community, and plans for future utilities as reasons for its upward trajectory. Many community members are actively participating in a buy contest, and anticipating a new ATH.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions about the Epstein files and Trump's potential involvement, with some users calling for their release while others defend him. Community members are also debating the stock's valuation and the broader implications of Trump's policies on the economy and international relations. The stock is highly divisive, with many users expressing strong opinions for and against Trump and his company.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending as the FDA considers the ineffectiveness of phenylephrine, an ingredient in popular decongestants like Sudafed PE, potentially impacting sales. Despite this, some analysts remain bullish, citing attractive entry points and a recent addition to the S&P 500, with the community actively monitoring price movements for potential buying opportunities.

Krypto Cock is a meme-powered crypto project with real onchain utility. Born from the lessons of past market cycles, $COCK blends humor, culture, and technology to create a unique community-driven ecosystem.  The project is focused on: • Building lightweight mini-apps for Farcaster and other onchain platforms • Developing an engaged, growing community • Delivering consistent, high-quality content • Offering practical onchain tools and experiences • Led by a team with years of crypto and product experience  $COCK aims to make the crypto experience more fun, accessible, and connected, without sacrificing purpose or quality.

CockCardano

$COCK.X is trending as the community rallies around the upcoming launch of Cocky Wings LLC, a real-world food business associated with the Cardano-based meme coin. Community members highlight the potential for passive income through staking and are excited about the partnership with $SNEK.X and the presence at the South Carolina Gamecocks home game.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending due to a significant stock drop following a weaker-than-expected outlook, driven by tariff concerns and slowing US sales. Community discussions revolve around whether this dip presents a buying opportunity, with some citing international growth potential and others highlighting increased competition and changing consumer preferences. The overall sentiment is bearish, with analysts downgrading the stock and investors questioning the company's growth strategy.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a recent analyst downgrade impacting investor sentiment, while some community members view the dip as a buying opportunity. Community talking points include the sustainability of AMD's growth, competition with NVIDIA and Broadcom, and potential price targets. Despite the selloff, some express confidence in AMD's long-term prospects, particularly in the AI and data center markets.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending amid discussions about its new corporate name and ticker symbol after Overstock acquired the rights, sparking confusion among investors. The community is buzzing about the potential of Tzero, a blockchain platform associated with the company, and its possible impact on preventing naked shorting, drawing comparisons to the $GME saga. Some traders are expressing skepticism while others speculate on Ryan Cohen's next move and the potential for new stores.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anavex Life Sciences slipped in after-hours trading on Monday after the company said it plans to raise&nbsp;as much as $300 million by selling shares.The stock closed at $11.48 on Monday, up 3.3% for the day, before slipping 1% to $11.37 in after-hours trading.The stock offering comes on the heels of its latest quarterly results,&nbsp;which showed net loss was $11.2 million, or $0.13 a share, compared with a loss of $10.5 million in the same period last year.&nbsp;The company had $115.8 million in cash at the end of March and said that it would fund the company for about four years.In April, Anavex disclosed an update on the long-term data on its Alzheimer’s candidate, blarcamesine. According to new data released, the drug slowed cognitive decline in early-stage Alzheimer’s patients over&nbsp;four years.&nbsp;The results were disclosed at the AD/PD 2025 conference, and they hint that the treatment may have a disease-modifying effect if started early and taken continuously.The drug has also been well tolerated. No&nbsp;significant safety issues were reported, and dizziness, the most common side effect, was reduced by tweaking the dose schedule.Anavex has also wrapped up enrollment for a mid-stage trial of its schizophrenia drug, Anavex 3-71, with results expected in the second half of the year.&nbsp;Separately, 74 patients remain on long-term blarcamesine therapy through a Compassionate Use Program, with some having taken the drug daily for over nine years.On Stocktwits, retail sentiment for Anavex was ‘extremely bullish’ amid ‘high’ message volume.One user viewed the shelf registration as a bullish signal, suggesting that Anavex may be positioning itself for a potential EMA approval.&nbsp;They speculated the filing could be tied to plans for standalone distribution or as a strategic move to strengthen the company’s hand in partnership talks, calling it “nothing but good news” for long-term holders.<stembedurl>https://stocktwits.com/PartyNaked/message/620947957</stembedurl>Another user said that the S-3 filing doesn’t mean an immediate offering, but rather gives the company flexibility to raise funds if needed, particularly after a major catalyst like an EMA decision.&nbsp;They called the move smart and standard for biotech firms, arguing it allows Anavex to act quickly if the stock jumps post-approval and strengthens its negotiating position with potential partners.<stembedurl>https://stocktwits.com/kay91667/message/620942567</stembedurl>Anavex’s stock has declined 5.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avanex Life Sciences (AVXL) said it plans to raise up to $300 million by selling shares. (Photo credit: Getty Images)

Anavex Life Sciences Stock Falls After Hours On $300M Raise Plan; Retail Traders Think It’s A ‘Smart’ Move 

The after-hours move followed Anavex’s recent completion of enrollment for a mid-stage schizophrenia trial, with top-line results expected later this year. 

Equity

Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Medical Stocks Lagging  Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday. The stocks trending the most on the Stocktwits platform include Webull, SharpLink, Anavex Life Sciences, BigBear.ai, and Oscar Health.1. Webull Corp. (BULL)<img src="https://news.stocktwits-cdn.com/BULL_png_3a86d4a0fc.webp" alt="BULL.png">2. SharpLink Gaming Ltd. (SBET)<img src="https://news.stocktwits-cdn.com/SBET_png_ddf51dbef1.webp" alt="SBET.png">3. Anavex Life Sciences Corp. (AVXL)<img src="https://news.stocktwits-cdn.com/AVXL_png_b962881047.webp" alt="AVXL.png">4. BigBear.ai Holdings Inc. (BBAI)<img src="https://news.stocktwits-cdn.com/BBAI_png_3156927dd7.webp" alt="BBAI.png">5. Oscar Health Inc. (OSCR)<img src="https://news.stocktwits-cdn.com/OSCR_png_e8f637dd66.webp" alt="OSCR.png">Disclaimer: Stocktwits' "Why It's Trending" summary is AI-generated and may contain errors.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-us-make-fortune-if-big-beautiful-bill-is-passed-but-house-republicans-could-sink-it/chF0ot3RTyE">Trump Says US Will ‘Make A Fortune’ If The Big Beautiful Bill Is Passed, But House Republicans Could Sink It</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 06, 2024 in New York City as the market opened after the worst crash since 2022

Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday.

Lightning Round: Sell Viking Therapeutics, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, Transocean, and DuPont...

Anavex Life Sciences Corp., a small-cap biotech specializing in neurodegenerative and neurodevelopmental diseases, emerged as the top pick among retail investors in a recent Stocktwits poll.&nbsp;Nearly 45% of respondents believe Anavex will outperform in the first quarter of 2025, compared to 33% for Novavax and 9% for Rigel Pharmaceuticals.<stembedurl>https://stocktwits.com/StocktwitsPolls/message/599783274</stembedurl>Alzheimer’s Therapy MomentumAnavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73), whose European Marketing Authorization Application was&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/avxl-stock-rises-on-q4-results-ema-nod-for-blarcamesine/cJazDmdRj5">accepted</a> last month.&nbsp;Promising trial results showed three years of continuous blarcamesine treatment significantly reduced clinical decline in early Alzheimer’s patients, with no safety issues reported.&nbsp;That positions the drug as a potential breakthrough, especially as interest in Alzheimer’s therapies intensifies following recent setbacks for rivals like Cassava Sciences.The company’s stock surged over 76% in 2024 but is down 6% year-to-date, with a high short interest of 24.5% as per Koyfin data.&nbsp;Anavex reported $132.2 million in cash reserves as of Sept. 30, 2024, and projects a four-year cash runway at its current burn rate.Vaccine Maker Eyes RecoveryNovavax has maintained momentum after a 68% gain in 2024, with shares up nearly 6% this year.&nbsp;The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvax-stock-is-undervalued-say-retail-investors/chGWtkSRZy">recovered</a> from an FDA clinical hold on its COVID-19 and flu combination vaccine late last year, thanks to a $50 million milestone payment under its Sanofi partnership and increasing hopes for a bird flu vaccine.&nbsp;Novavax holds the largest market cap among the three at $1.38 billion. It has $909.5 million in cash and a manageable debt load of $262 million, which many retail investors see as an advantage.&nbsp;It also has a high short interest of 24.5%.Under-The-Radar Bet?Rigel Pharmaceuticals focuses on autoimmune and hematologic diseases. The company recently received orphan drug designation for R289, a treatment for lower-risk myelodysplastic syndromes.&nbsp;A growing portfolio of approved therapies, such as TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for acute myeloid leukemia has also boosted retail sentiment.On Monday, the company said it expects fourth-quarter revenue of $57.6 million, up 61% year-over-year and above a Wall Street estimate of $47.4 million. It also projected 2025 revenue of $200-$210 million, better than an expected $193.5 million.Rigel’s stock rose 15% in 2024 and remained nearly flat in 2025. As of Dec. 31, 2024, it had estimated cash reserves of $77.3 million.&nbsp;Rigel’s short interest is relatively low at 3.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Anavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73). | Image source: Getty Images 

Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.

Anavex Life Sciences Corp. shares rocketed over 27% on Monday, hitting their highest levels since February 2023, fueled by a mix of positive earnings results and regulatory progress in Europe.The biopharma company, focused on neurodegenerative and neurodevelopmental diseases, reported a fiscal fourth-quarter loss of $11.6 million, or an adjusted $0.14 per share, compared to a loss of $10.1 million in the year-ago period.&nbsp;While research and development (R&amp;D) and overhead costs rose, the per-share loss was narrower than the FactSet consensus estimate of $0.16.Anavex also highlighted a strong cash position, with $132.2 million in reserves, which the company says will provide a four-year runway at current burn rates.Creating more buzz was news that the European Medicines Agency (EMA) accepted the Marketing Authorization Application for blarcamesine (ANAVEX 2-73), an investigational oral drug for Alzheimer’s disease.&nbsp;Anavex’s Head of R&amp;D, Juan Carlos Lopez-Talavera, said: "The EMA filing acceptance for blarcamesine to review the Marketing Authorization Application potentially brings us a step closer offering broader patient access to a new treatment option in Europe, and we look forward to continued engagement with the EMA.”CEO Christoper Missling said, "We are excited about the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing and our team remains deeply committed to executing on our momentum.”<figure class="image"><img style="aspect-ratio:1326/1056;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_poll_sentiment_and_message_volume_Dec_24_fe40cd4f12.png" alt="AVXL poll sentiment and message volume Dec 24.png" width="1326" height="1056"><figcaption>AVXL poll, sentiment and message volume on Dec 24 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits celebrated the news, with sentiment shifting sharply to ‘bullish’ from ‘neutral.’&nbsp;Many hailed the EMA filing as a significant milestone, with one user claiming very high approval rates by the European regulator for “accepted drug candidates in 2024 that aren't withdrawn.”<stembedurl>https://stocktwits.com/Guzzi62/message/597573043</stembedurl><stembedurl>https://stocktwits.com/PhillipHerass/message/597572113</stembedurl><stembedurl>https://stocktwits.com/Logic102/message/597572650</stembedurl>According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10499418/">study</a> published last year in the Clinical and Translational Science, an official journal of the American Society for Clinical Pharmacology and Therapeutics, the EMA was found to have the highest approval rate (93.8%) for non-oncology products when compared with Swiss and U.S. regulators. The data analyzed decisions between 2009 and 2018 on new active substances.The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sava-stock-plunges-after-alzheimers-trial-fails/cJIf1KdRgh">reported</a> disappointing results for its candidate simufilam last month.&nbsp;D. Boral Capital had noted Anavex’s neuroprotective mechanism could position blarcamesine as a superior option, reiterating a ‘Buy’ rating with a $46 price target.Anavex shares are now up 88% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

EMA European Medicines Agency at Canary Wharf on 5th November 2024 in London, United Kingdom. (photo by Mike Kemp/In Pictures via Getty Images)

Anavex Sciences Soars On Earnings Relief, EU Filing Acceptance For Alzheimer’s Drug: Retail’s Overjoyed

The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences reported disappointing results for its candidate simufilam last month.

What To Expect in the Markets This Week

Coming up: Shortened market hours around the Christmas holiday, consumer confidence, new home sales, initial jobless claimsGetty ImagesKey TakeawaysMarkets are closed Wednesday for Christmas.On...

This Week’s Hottest Themes: Biotech (RFK Jr. Meddling), Space (Trump's Space Force),&nbsp; AI (The Theme of the Year)&nbsp;WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in sectors actively drawing capital. This targeted approach, combined with real-time news surveillance, helps us uncover stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.Here's a list of today's most important names:1. Cassava Sciences (NASDAQ: SAVA)Background: Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer’s disease. Its investigational drug, Simufilam, has been central to its research efforts.The News: Cassava's stock took a dramatic plunge after disappointing Phase 3 trial results for Simufilam, followed by a social media storm triggered by Martin Shkreli’s scathing critique of the drug’s efficacy. Shkreli, calling Simufilam’s mechanism “implausible,” encouraged short-sellers, predicting a sharp decline in the stock. The failure of the trial and Shkreli’s influence sent shares tumbling by more than 85%, from nearly $30 per share to under $5.What It Means: This setback emphasizes the significant risks in Alzheimer's drug development. With most Alzheimer’s trials failing, investors now question the credibility of Cassava’s lead drug. While the company still has resources to pivot, the stock’s credibility has been deeply shaken, and the road ahead is uncertain.Stock Reaction: Yesterday the stock opened at $30 but closed near $5, reflecting a swift and steep sell-off. The market’s reaction shows how quickly investor sentiment can turn negative on biotech stocks, particularly in high-risk, high-reward sectors like Alzheimer’s treatment.&nbsp;2. Poseida Therapeutics (NASDAQ: PSTX)Background: Poseida is a biopharmaceutical company specializing in gene therapies, particularly CAR-T treatments for cancer.The News: Poseida announced a significant partnership with Roche, securing $110 million upfront and up to $1 billion in potential milestones. This deal is aimed at accelerating Poseida's CAR-T therapies and other cell and gene therapy technologies.What It Means: This collaboration is a major validation for Poseida’s technology, especially in the competitive CAR-T space, which has attracted attention due to its potential to treat cancers. The cash infusion from Roche is expected to fuel further research and development.Stock Reaction: Poseida opened at $9.26, up over 200%, rising slightly to close at $9.38. The market responded favorably to the news, viewing the Roche deal as a solid indication of Poseida’s future potential in the cancer treatment landscape.&nbsp;3. KULR Technology Group (NYSE: KULR)Background: KULR specializes in thermal management technologies for energy storage and aerospace.The News: KULR Technology Group has received a U.S. Navy contract to develop its Internal Short Circuit (ISC) technology to operate at higher temperatures. This upgrade is important for both military and commercial applications, especially in aviation where it aligns with safety standards. The ISC devices, originally developed with NASA and NREL, simulate controlled thermal runaway in lithium-ion cells for more accurate and safer testing of battery behavior in extreme conditions.What It Means: The Navy contract could serve as a major stepping stone for KULR, providing the company with exposure to one of the most demanding industries for thermal solutions. This deal not only enhances KULR’s credibility but may also open doors for similar partnerships in the aerospace and defense sectors.Stock Reaction: The stock opened at $0.80 and climbed another 20% reaching $0.96 by mid-morning on volume that is 1,000%+ higher than average.&nbsp;4. POET Technologies (NASDAQ: POET)Background: POET is a leader in photonics technology, designing advanced semiconductor solutions aimed at AI, telecommunications, and data storage.The News: POET Technologies (NASDAQ: POET) is ramping up production of its optical engines to meet the increasing demand from AI applications. A recent report highlighted that while many companies in the UK are adopting AI, few have integrated it into their manufacturing processes, which could hinder innovation and productivity. The report suggests that government support and regulations could help accelerate AI adoption in industries.What It Means: As AI applications continue to expand, POET’s new platform could be a game-changer. The optical interposer aims to address the bottlenecks in data processing by enabling faster, more efficient communication between chips, which is crucial for AI and big data.Stock Reaction: POET opened at $4.38 and rose to $5.35 (up 22%) by mid-day on volume 3x higher than average.&nbsp;5. SurgePays (NASDAQ: SURG)Background: SurgePays provides financial services and prepaid wireless solutions for underserved markets.The News:&nbsp;SurgePays (SURG) has integrated its ClearLine marketing platform with PAX smart payment terminals, allowing merchants to deliver real-time promotions and offers during transactions. This integration leverages existing hardware to enhance customer engagement and streamline marketing efforts, helping retailers boost loyalty and sales. SurgePays aims to scale its retail presence by utilizing PAX's wide reach in the payment terminal industry.What It Means: SurgePays continues to capitalize on the significant need for affordable financial services and wireless solutions in underserved communities. This strong performance suggests the company’s business model is scaling effectively, positioning it well for future growth.Stock Reaction: SurgePays opened at $2.00 and surged to $2.20, up 10%, trading average volume.&nbsp;6. TOYO Ventures Holdings (NASDAQ: TOYO)Background: TOYO Co., Ltd. is a solar solutions company focused on becoming a full-service provider in the global market. It integrates all stages of the solar power supply chain, including wafer and silicon production, solar cell manufacturing, and photovoltaic module production. TOYO is positioned to produce high-quality solar cells at a competitive scale and cost.The News: TOYO Co., Ltd (Nasdaq: TOYO) has secured a $150 million contract to supply high-efficiency solar cells to a major solar module manufacturer. The agreement will support solar module production in India and the U.S., leveraging TOYO’s advanced manufacturing capabilities in Vietnam and Ethiopia. This contract highlights the company's commitment to sustainable energy and the global shift towards renewable resources.What It Means: The $150 million contract is a major win for TOYO Co., Ltd, solidifying its role as a key player in the solar energy sector. It highlights the company’s advanced manufacturing capabilities and global reach, particularly in India and the U.S. For the market, the deal signals continued growth in the solar industry, boosting confidence in renewable energy technologies and potentially attracting more investment. TOYO’s expanded presence in key markets could strengthen its competitive position as demand for efficient solar cells rises..Stock Reaction: Shares opened at $5.56, up 39% to retrace to $4.50 by mid-morning and closing at $5.41 on eye-poping 1,500x average volume.&nbsp;&nbsp;7. Anavex Life Sciences (NASDAQ: AVXL)Background:&nbsp;Anavex Life Sciences develops treatments for neurodegenerative disorders like Alzheimer's and Parkinson's. Its lead drug, ANAVEX®2-73, has shown positive results in Phase 2 trials, while the company is also developing ANAVEX®3-71 for Alzheimer's.The News:Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug, blarcamesine (ANAVEX®2-73), to the European Medicines Agency (EMA) for the treatment of Alzheimer’s disease. Blarcamesine, an orally administered small molecule, showed significant clinical improvement in patients over 48 weeks, with better efficacy than approved therapies and a slower rate of neurodegeneration in early Alzheimer's patients. Its safety profile eliminates the need for routine MRI monitoring, making it a promising treatment option.What It Means:&nbsp;The MAA submission for blarcamesine to the EMA is a positive development for Anavex Life Sciences, potentially boosting its stock if approved. If successful, blarcamesine could open new revenue streams and strengthen investor confidence. For the broader market, this signals progress in Alzheimer’s treatment, potentially drawing more investment into biotech, especially in neurodegenerative diseases.Stock Reaction: Anavex opened at $10.30 up 10% from Monday's close, but cratered almost 20% from that high by mid-afternoon closing nearly flat from the previous day's close on slightly higher than average volume.&nbsp;&nbsp;Be The First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST&nbsp;SpaceMobile (NASDAQ: ASTS) which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;&nbsp;<hr>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WealthyVC">Follow us on Twitter</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/wealthyventurecapital/">Follow us on Instagram</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/TheWealthyVentureCapitalist/?locale=zh_CN">Follow us on Facebook</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

Shares of Anavex Life Sciences Corp. (<a class="mention" data-mention="$AVXL" data-symbol-id="AVXL" href="https://stocktwits.com/symbol/AVXL" target="_blank">$AVXL</a>) surged as much as 11% in pre-market trading Tuesday after the company filed for approval of its oral Alzheimer's drug with the European Medicines Agency (EMA).The biopharmaceutical company is looking for market authorization for blarcamesine, an oral treatment designed for Alzheimer’s Disease.&nbsp;The drug has shown promising results in clinical trials with patients improving significantly over a 48-week period. The company cited ADAS-Cog13 scores improving by more than 2 points, which means the treatment may have helped slow cognitive decline.The company also said that its treatment is more clinically effective as compared to approved therapies while slowing neurodegeneration in early-stage Alzheimer’s patients,Anavex claims blarcamesine’s advantages include its ease of use – taken just once a day, it does not require routine MRIs and a favorable safety profile."Blarcamesine's safety and efficacy profile could represent a novel treatment that could be complementary or an alternative to anti-beta amyloid monoclonal antibody drugs,” said Juan Carlos Lopez-Talavera, the head of research and development at Anavex.&nbsp;D. Boral Capital has maintained a ‘Buy’ rating on Anavex with a $46 price target after Cassava Sciences' (<a class="mention" data-mention="$SAVA" data-symbol-id="SAVA" href="https://stocktwits.com/symbol/SAVA" target="_blank">$SAVA</a>) Phase 3 trial for simufilam&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sava-stock-plunges-after-alzheimers-trial-fails/cJIf1KdRgh">failed</a> in mild-to-moderate Alzheimer's disease.&nbsp;The investment bank believes that Anavex’s treatment, which works by activating the sigma-1 receptor, could give it an edge over therapies like simlufilam that focus on narrower mechanisms.&nbsp;<figure class="image"><img style="aspect-ratio:1303/296;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_26_090241_50b7cdc087.png" alt="Screenshot 2024-11-26 090241.png" width="1303" height="296"><figcaption>Anavex Life Sciences Corp. Sentiment and Message Volume on Nov 26 as of 9:00 a.m. ET | Source: Stocktwits</figcaption></figure>Retail sentiment around Anavex jumped into the ‘extremely bullish’ (80/100)&nbsp; territory in pre-market trading on Tuesday along with an uptick in chatter to ‘extremely high’ (77/100).Retail investors on Stockwits were cheering the company’s first-ever EMA submission.<stembedurl>https://stocktwits.com/5RingsPatsRule/message/594105457</stembedurl><stembedurl>https://stocktwits.com/Factanonverba/message/594105443</stembedurl><stembedurl>https://stocktwits.com/Minnesotastockdude/message/594069500</stembedurl>Anavex is expected to report its fourth-quarter earnings on Friday with Wall Street expecting a loss of $0.16 per share on no revenue.&nbsp;The stock has gained 69% so far this year, outperforming the broader market.For updates and corrections email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sava-stock-plunges-after-alzheimers-trial-fails/cJIf1KdRgh">Cassava Sciences Stock Craters After Alzheimer’s Disease Trial Flops: Retail’s Devastated</a>

Anavex is expected to report its fourth-quarter earnings on Friday, Nov. 29. | Source: Pixabay

Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon

D. Boral Capital believes Anavex’s Alzheimer’s treatment is superior to Cassava Sciences' approach.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

$APP

$MSTR

$HOOD

other (drop a comment)

The S&amp;P 500 rebalance announcement is today — which stock do you think has the best shot at getting added?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.14	--	--	N/A
Q3 '25	-$0.14	-$0.16	-12.41%	MISSED
Q2 '25	-$0.15	-$0.13	13.33%	BEAT
Q1 '25	-$0.17	-$0.14	17.65%	BEAT
Q4 '24	-$0.16	-$0.14	14.29%	BEAT

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest AVXL News

AVXL Anavex Life Sciences Corp